临床放射学杂志
臨床放射學雜誌
림상방사학잡지
JOURNAL OF CLINICAL RADIOLOGY
2001年
5期
388-391
,共4页
谢晓东%廖正银%卢武胜%官泳松%费泽军%文春玉%焦河%胡淑雨
謝曉東%廖正銀%盧武勝%官泳鬆%費澤軍%文春玉%焦河%鬍淑雨
사효동%료정은%로무성%관영송%비택군%문춘옥%초하%호숙우
上腔静脉综合征%肺肿瘤%溶栓%支架
上腔靜脈綜閤徵%肺腫瘤%溶栓%支架
상강정맥종합정%폐종류%용전%지가
目的探讨上腔静脉内支架置入及局部溶栓治疗原发性肺癌合并上腔静脉综合征(SVCS)的临床价值。材料与方法采用经皮穿刺股静脉插管的方法对15例肺癌合并SVCS患者分别向狭窄的上腔静脉置入1枚直径10~14mm、长60~80mm的镍钛记忆合金支架,其中5例经导管注入尿激酶30~42万IU局部溶栓治疗。结果 15例支架置入一次成功,上腔静脉血流恢复通畅。14例患者SVCS症状很快消除;1例合并血栓者经局部溶栓治疗后症状显著改善。随访3个月~5年,6例患者成活3个月~3年,无复发;5例患者术后4个月~2年因肺癌死亡时亦无复发。4例患者术后短期内复发支架内血栓阻塞,经局部溶栓治疗后症状显著改善。结论血管内支架治疗肺癌合并SVCS是一种有效的姑息治疗方法。及时局部溶栓治疗是防止近期复发的良好手段。为了延长这类患者的生存期,必须重视肺癌本身的治疗。
目的探討上腔靜脈內支架置入及跼部溶栓治療原髮性肺癌閤併上腔靜脈綜閤徵(SVCS)的臨床價值。材料與方法採用經皮穿刺股靜脈插管的方法對15例肺癌閤併SVCS患者分彆嚮狹窄的上腔靜脈置入1枚直徑10~14mm、長60~80mm的鎳鈦記憶閤金支架,其中5例經導管註入尿激酶30~42萬IU跼部溶栓治療。結果 15例支架置入一次成功,上腔靜脈血流恢複通暢。14例患者SVCS癥狀很快消除;1例閤併血栓者經跼部溶栓治療後癥狀顯著改善。隨訪3箇月~5年,6例患者成活3箇月~3年,無複髮;5例患者術後4箇月~2年因肺癌死亡時亦無複髮。4例患者術後短期內複髮支架內血栓阻塞,經跼部溶栓治療後癥狀顯著改善。結論血管內支架治療肺癌閤併SVCS是一種有效的姑息治療方法。及時跼部溶栓治療是防止近期複髮的良好手段。為瞭延長這類患者的生存期,必鬚重視肺癌本身的治療。
목적탐토상강정맥내지가치입급국부용전치료원발성폐암합병상강정맥종합정(SVCS)적림상개치。재료여방법채용경피천자고정맥삽관적방법대15례폐암합병SVCS환자분별향협착적상강정맥치입1매직경10~14mm、장60~80mm적얼태기억합금지가,기중5례경도관주입뇨격매30~42만IU국부용전치료。결과 15례지가치입일차성공,상강정맥혈류회복통창。14례환자SVCS증상흔쾌소제;1례합병혈전자경국부용전치료후증상현저개선。수방3개월~5년,6례환자성활3개월~3년,무복발;5례환자술후4개월~2년인폐암사망시역무복발。4례환자술후단기내복발지가내혈전조새,경국부용전치료후증상현저개선。결론혈관내지가치료폐암합병SVCS시일충유효적고식치료방법。급시국부용전치료시방지근기복발적량호수단。위료연장저류환자적생존기,필수중시폐암본신적치료。
Objective To evaluate expansible metallic stent implantation and local thrombolysis in the treatment of superior vena cava syndrome (SVCS) due to primary lung carcinoma. Materials and Methods Nickel titanium memorial alloying stent, 10~14mm in diameter and 60~80mm in length, was implanted in 15 patients with SCVS caused by lung cancer. The procedure was carried out through percutaneous puncture of the right femoral vein. Results Successful positioning of the stent and the patency of SVC were achieved in all patients. The symptoms of SVCS disappeared immediately in 14 patients. A following-up period lasting 3 months~5 years showed that 5 patients died of tumor progression (4 months~2 years) and 6 patients were survival (3 months~3 years). In 4 patients, thromboembolism of the stent occurred shortly after the procedure, the symptoms were improved after local thrombolytic therapy via a catheter. Conclusion Stent implantation for SVCS due to lung cancer seems to be an effective palliative treatment. Local thrombolytic therapy is useful for short-term recurrence. To prolong the survival stage, great attention to the treatment of lung cancer per se should be paid.